BTIG, Inari
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
24/7 Wall St. on MSN3d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend WinnersHere are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
AvidXchange Holdings Inc (AVDX) stock saw a decline, ending the day at $9.8 which represents a decrease of $-0.32 or -3.16% from the prior close of $10.12. The stock opened at $10.06 and touched a low ...
BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...
“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback